Drugs / MKND-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06532942 | May → Oct 2024 overdue | — | Mannkind Corporation | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MKND-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06532942 ↗ |
| Route | Inhaled | “administered via oral inhalation” NCT06532942 ↗ |